WO2004066967A3 - Method and kit for reducing the symptoms of peripheral vascular disease - Google Patents

Method and kit for reducing the symptoms of peripheral vascular disease Download PDF

Info

Publication number
WO2004066967A3
WO2004066967A3 PCT/US2004/000941 US2004000941W WO2004066967A3 WO 2004066967 A3 WO2004066967 A3 WO 2004066967A3 US 2004000941 W US2004000941 W US 2004000941W WO 2004066967 A3 WO2004066967 A3 WO 2004066967A3
Authority
WO
WIPO (PCT)
Prior art keywords
peripheral vascular
symptoms
vascular disease
reducing
kit
Prior art date
Application number
PCT/US2004/000941
Other languages
French (fr)
Other versions
WO2004066967B1 (en
WO2004066967A2 (en
Original Assignee
Dimera Inc
Hermsmeyer R Kent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dimera Inc, Hermsmeyer R Kent filed Critical Dimera Inc
Priority to JP2006502824A priority Critical patent/JP2006515890A/en
Priority to EP04702515A priority patent/EP1594510A4/en
Publication of WO2004066967A2 publication Critical patent/WO2004066967A2/en
Publication of WO2004066967A3 publication Critical patent/WO2004066967A3/en
Publication of WO2004066967B1 publication Critical patent/WO2004066967B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

A method for reducing the symptoms of peripheral vascular disease wherein a chemical agent that reduces peripheral vascular hyperreactivity in response to a stimulus for contraction of peripheral vascular musculature is administered to a subject in need thereof. Kits for administering the chemical agent to reduce the symptoms of peripheral vascular disease.
PCT/US2004/000941 2003-01-21 2004-01-15 Method and kit for reducing the symptoms of peripheral vascular disease WO2004066967A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2006502824A JP2006515890A (en) 2003-01-21 2004-01-15 Methods and kits for symptoms of peripheral vascular disease
EP04702515A EP1594510A4 (en) 2003-01-21 2004-01-15 Method and kit for reducing the symptoms of peripheral vascular disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/348,570 2003-01-21
US10/348,570 US7572780B2 (en) 2003-01-21 2003-01-21 Method and kit for reducing the symptoms of peripheral vascular disease

Publications (3)

Publication Number Publication Date
WO2004066967A2 WO2004066967A2 (en) 2004-08-12
WO2004066967A3 true WO2004066967A3 (en) 2005-03-03
WO2004066967B1 WO2004066967B1 (en) 2005-04-14

Family

ID=32712580

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/000941 WO2004066967A2 (en) 2003-01-21 2004-01-15 Method and kit for reducing the symptoms of peripheral vascular disease

Country Status (4)

Country Link
US (3) US7572780B2 (en)
EP (1) EP1594510A4 (en)
JP (1) JP2006515890A (en)
WO (1) WO2004066967A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013078422A2 (en) 2011-11-23 2013-05-30 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
HUE046963T2 (en) 2012-07-27 2020-04-28 Glia Llc Compositions and treatment for eye diseases and disorders
US9381231B2 (en) 2012-10-09 2016-07-05 University Of Florida Research Foundation, Inc. Use of relaxin to restore maternal physiology in pregnancies conceived by assisted reproductive technologies
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
MX2016013693A (en) 2014-07-29 2017-10-31 Therapeuticsmd Inc Transdermal cream.
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0399432A2 (en) * 1989-05-25 1990-11-28 Takeda Chemical Industries, Ltd. Transdermal therapeutic composition
US5612051A (en) * 1995-11-17 1997-03-18 Yue; Samuel K. Method of treating involuntary muscle dysfunction with relaxin hormone
US20020156090A1 (en) * 2000-10-17 2002-10-24 Day Wesley W. Methods and kits for improving vascular health

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2408345A1 (en) * 1976-11-30 1979-06-08 Besins Jean Louis NEW COMPOSITION WITH ANTI-CONCEPTIONAL ACTION
DE3514724A1 (en) 1985-04-24 1986-10-30 Albin F. Dr. 4200 Oberhausen Jereb Ointment for the prevention and treatment of disorders of the eyes and skin
US4788062A (en) 1987-02-26 1988-11-29 Alza Corporation Transdermal administration of progesterone, estradiol esters, and mixtures thereof
US4900734A (en) * 1987-08-27 1990-02-13 Maxson Wayne S Novel pharmaceutical composition containing estradiol and progesterone for oral administration
US5422119A (en) * 1987-09-24 1995-06-06 Jencap Research Ltd. Transdermal hormone replacement therapy
US4800734A (en) * 1987-11-02 1989-01-31 White Consolidated Industries, Inc. Room air conditioner
US5543150A (en) 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
US5859001A (en) * 1996-01-11 1999-01-12 University Of Florida Research Foundation, Inc. Neuroprotective effects of polycyclic phenolic compounds
WO1995026974A1 (en) 1994-04-04 1995-10-12 Meiji Milk Products Co., Ltd. Novel progesterone compound and use thereof
US5696123A (en) * 1994-09-17 1997-12-09 Boehringer Ingelheim Kg Neurokinin antagonists
US6613757B1 (en) 1994-09-22 2003-09-02 Board Of Regents, The University Of Texas System Combination of prostacyclin with an estrogen or progestin for the prevention and treatment of atherosclerotic vascular disease including preeclampsia and for the treatment of hypertension, and for hormone replacement therapy
JPH08180574A (en) * 1994-12-28 1996-07-12 Teac Corp Disc unit
US5744463A (en) 1996-06-03 1998-04-28 Bair; Glenn O. Treatment of side effects of progestins and progesterone analogues used for birth control
IT1283102B1 (en) * 1996-06-06 1998-04-07 Permatec Nv THERAPEUTIC COMPOSITION FOR THE TRANSDERMAL ADMINISTRATION OF AN ESTROGENIC OR PROGESTINIC ACTIVE SUBSTANCE OR OF THEIR MIXTURES
US6228852B1 (en) * 1996-07-12 2001-05-08 Carolyn V. Shaak Transdermal application of naturally occurring steroid hormones
US5985861A (en) * 1996-11-04 1999-11-16 Columbia Laboratories, Inc. Progesterone for treating or reducing ischemia
US6056972A (en) * 1997-02-26 2000-05-02 Dimera, Llc Method for reducing coronary artery reactivity
US6440954B1 (en) * 1997-04-18 2002-08-27 President And Fellows Of Harvard College Inhibition of vascular smooth muscle cell proliferation
US5998638A (en) * 1997-05-02 1999-12-07 American Home Products Corporation Ester salt of 5α-pregn-16-en-3β-ol-20-one 3-sulfate
CA2289095A1 (en) 1997-05-02 1998-11-12 American Home Products Corporation Pregnane 3,20 diol mono- and di-sulphates
CA2289006A1 (en) 1997-05-02 1998-11-12 American Home Products Corporation Pregnan-3-ol-20-ones
US5968918A (en) * 1997-10-17 1999-10-19 Kanda; Iwao Method for the prevention of coronary artery spasm
US5988918A (en) * 1998-04-24 1999-11-23 Johnson; Gary D. Flat folding writing instrument
AU2609401A (en) 1999-12-29 2001-07-09 Nicholas Kipshidze Apparatus and method for delivering compounds to a living organism
CA2496867A1 (en) 2002-08-28 2004-03-11 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment methods
EP1539268A1 (en) 2002-09-12 2005-06-15 Estrogen Vascular Technology, LLC Apparatus and method for delivering compounds to a living organism

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0399432A2 (en) * 1989-05-25 1990-11-28 Takeda Chemical Industries, Ltd. Transdermal therapeutic composition
US5612051A (en) * 1995-11-17 1997-03-18 Yue; Samuel K. Method of treating involuntary muscle dysfunction with relaxin hormone
US20020156090A1 (en) * 2000-10-17 2002-10-24 Day Wesley W. Methods and kits for improving vascular health

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] WALKER T.C.: "Use of testosterone propionate and estrogenic substance in treatment of essential hypertension, angina pectoris and peripheral vascular disease", XP002984534, Database accession no. 1943:5455 *
JOURNAL OF CLINICAL ENDOCRINOLOGY, vol. 2, 1942, pages 560 - 568 *
MYERS ET AL.: "Estrogen increase male rat aortic endothelial cell (RAEC) PGI2 release", PROSTAGLANDINS, LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, vol. 54, no. 6, 1996, pages 403 - 409, XP002984535 *

Also Published As

Publication number Publication date
US20090275544A1 (en) 2009-11-05
US7572780B2 (en) 2009-08-11
EP1594510A2 (en) 2005-11-16
US20120232046A1 (en) 2012-09-13
US20040142913A1 (en) 2004-07-22
JP2006515890A (en) 2006-06-08
US8182833B2 (en) 2012-05-22
EP1594510A4 (en) 2008-07-23
WO2004066967B1 (en) 2005-04-14
WO2004066967A2 (en) 2004-08-12
US8420111B2 (en) 2013-04-16

Similar Documents

Publication Publication Date Title
WO2004066967A3 (en) Method and kit for reducing the symptoms of peripheral vascular disease
WO2004103959A3 (en) Heterocyclic compounds and uses thereof
WO2001085154A3 (en) Method of treating immune pathologies with low dose estrogen
WO2005097119A3 (en) Pten inhibitors
ZA200608024B (en) Use of flibanserin in the treatment of premenstrual and other female sexual disorders
HK1075010A1 (en) Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
EP1767197A3 (en) Treatment of Alzheimer's disease with inhibitors of cell cycle re-entry and progression
WO2004037262A3 (en) Immediate release topical pharmaceutical formulation for enhancement of female sexual desire and responsiveness
WO2006004449A3 (en) A combination composition
WO2004090539A3 (en) Methods of determining efficacy of treatments of inflammatory diseases of the bowel
EP1750734A4 (en) Method of preparation and use of fibrinolytic enzymes in the treatment of disease
PL1693064T3 (en) Treating weight loss in patients suffering from inflammatory bowel diseases with S. boulardii
WO2002074992A3 (en) Phosphodiesterase 4d genes related to human stroke
WO2006042021A3 (en) Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
WO2004098517A3 (en) Methods of hormonal treatment utilizing extended cycle contraceptive regimens
WO2006016262A8 (en) Combination of a selective noradrenaline reuptake inhibitor and a pdev inhibitor
WO2004103407A3 (en) Composition comprising a pde4 inhibitor and a pde5 inhibitor
CA2387486A1 (en) Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
WO2004028548A3 (en) Inhibitors of the nitrix oxide synthase iii (nos iii) as neuroprotective agents
WO2006138571A3 (en) Composition and methods for treating complications associated with ingestion of a medicinal, chemical or biological substance
AU2003291536A1 (en) Method for the diagnosis and treatment of vascular disease
WO2006102899A3 (en) Oxaprozin or closely related compound for the treatment and prevention of
AU2003234976A1 (en) The use of the human urinary kininogenase in the manufacture of a medicine for treating and preventing cerebral embolism
WO2001026639A3 (en) Pharmaceutical composition of ateglinide and another antidiabeticagent

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
B Later publication of amended claims

Effective date: 20050207

WWE Wipo information: entry into national phase

Ref document number: 2006502824

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004702515

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004702515

Country of ref document: EP